Summary
Gastro-intestinal (GI) cancers, including gastro-esophageal junctional (GEJC), gastric (GC), colorectal (CRC) and pancreatic cancer (PC) are devastating malignancies that annually affect over 2 million persons worldwide and lead to more than 600,000 deaths (Globocan 2012). Given the current trends, the incidence of GI cancer is expected to increase further. Conventional therapies include chemo- and radiation therapy combined with surgery. However, amongst cancer patients, GI cancer patients have one of the poorest outcomes with a 5-year survival ranging from only 60% for CRC to a mere 5% for PC
At the moment, important steps are being taken to implement the highly specific anti-BMP4 low molecular weight antibodies (Dwarfbodies ®; DB, recently developed by us) in the clinic as a novel treatment strategy for gastro-intestinal (GI) cancers. To enable optimal treatment a diagnostic compendium is required. The CTC4BMP project aims to deliver a blood based method for patient stratification to identify patients that will benefit from the BMP4 inhibiting Dwarfbody therapy.
At the moment, important steps are being taken to implement the highly specific anti-BMP4 low molecular weight antibodies (Dwarfbodies ®; DB, recently developed by us) in the clinic as a novel treatment strategy for gastro-intestinal (GI) cancers. To enable optimal treatment a diagnostic compendium is required. The CTC4BMP project aims to deliver a blood based method for patient stratification to identify patients that will benefit from the BMP4 inhibiting Dwarfbody therapy.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/737612 |
| Start date: | 01-07-2017 |
| End date: | 31-12-2018 |
| Total budget - Public funding: | 150 000,00 Euro - 150 000,00 Euro |
Cordis data
Original description
Gastro-intestinal (GI) cancers, including gastro-esophageal junctional (GEJC), gastric (GC), colorectal (CRC) and pancreatic cancer (PC) are devastating malignancies that annually affect over 2 million persons worldwide and lead to more than 600,000 deaths (Globocan 2012). Given the current trends, the incidence of GI cancer is expected to increase further. Conventional therapies include chemo- and radiation therapy combined with surgery. However, amongst cancer patients, GI cancer patients have one of the poorest outcomes with a 5-year survival ranging from only 60% for CRC to a mere 5% for PCAt the moment, important steps are being taken to implement the highly specific anti-BMP4 low molecular weight antibodies (Dwarfbodies ®; DB, recently developed by us) in the clinic as a novel treatment strategy for gastro-intestinal (GI) cancers. To enable optimal treatment a diagnostic compendium is required. The CTC4BMP project aims to deliver a blood based method for patient stratification to identify patients that will benefit from the BMP4 inhibiting Dwarfbody therapy.
Status
CLOSEDCall topic
ERC-PoC-2016Update Date
27-04-2024
Images
No images available.
Geographical location(s)
Search
